bucladesine + fotemustine

This is a combination therapy of two drugs: **bucladesine** and **fotemustine**. Bucladesine is a cell-permeable analog of cyclic adenosine monophosphate (cAMP) that acts as a phosphodiesterase inhibitor and mimics endogenous cAMP, leading to activation of cAMP-dependent protein kinase pathways. It has been studied for its ability to promote physiological responses similar to cAMP, including effects on neuronal outgrowth and wound healing[6][7][8]. Fotemustine is an alkylating agent from the nitrosourea class used primarily as an antitumor cytostatic drug; it exerts its effect by causing DNA cross-linking and strand breaks, leading to inhibition of DNA replication and cell death[3]. The combination has been investigated in high-grade glioma/glioblastoma multiforme where local interstitial chemotherapy with sustained-release bucladesine pellets was combined with systemic intravenous fotemustine. This regimen showed improved survival rates compared to either treatment alone in clinical studies[2][4].

Other names

dibutyryl cyclic AMPdB-cAMP